Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 9901 participants.
Also called NCT01394952
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 9,901 participants
- Sponsor
- Registry
-
NCT01394952
-
- Other papers using this trial's data
- Biomarker Changes Associated With Both Dulaglutide and Cardiovascular Events in the REWIND Randomized Controlled Trial: A Nested Case-Control Post Hoc Analysis
- Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
- Dulaglutide and neurodegeneration biomarkers: REWIND post hoc analysis
- Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial
- Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trial
- Efficacy and Safety of Dulaglutide in Older Patients: A post hoc Analysis of the REWIND trial
- Erectile function in men with type 2 diabetes treated with dulaglutide: an exploratory analysis of the REWIND placebo-controlled randomised trial
- Exploring potential mediators of the cardiovascular benefit of dulaglutide in type 2 diabetes patients in REWIND
- Gender differences in cardiovascular risk, treatment, and outcomes: a post hoc analysis from the REWIND trial
- HbA1c Reduction in Dulaglutide-Treated Patients Irrespective of Duration of Diabetes, Microvascular Disease, and BMI: A Post Hoc Analysis From the REWIND Trial
- The effect of dulaglutide on stroke: an exploratory analysis of the REWIND trial
- Total cardiovascular or fatal events in people with type 2 diabetes and cardiovascular risk factors treated with dulaglutide in the REWIND trail: a post hoc analysis
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Argentina, Australia, Brazil, Bulgaria, Canada, Chile, Colombia, Czechia, Germany, Hungary, Latvia, Lithuania, Mexico, New Zealand, Poland, Puerto Rico, Romania, Russia, South Africa, South Korea, Spain, Sweden, Taiwan, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT01394952. Randomized; double masking; primary purpose treatment. Start 2011-07-22 (actual); primary completion 2018-08-21 (actual). Results posted on 2019-10-08.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)
- Acronym
- REWIND
- Condition
- Cardiovascular Disease
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- Dulaglutide
- Intervention (Drug)
- Placebo
- Lead sponsor
- Eli Lilly and Company
Record details
- Record id
cardio:ct-nct01394952- Content hash
db4ffc0d064cf1828b95940a9d60e45549479085df376e13fb0f09a95cb9ed68